Sarepta Therapeutics Tumbles 30% After Delay Of Eteplirsen Approval
October 27, 2014 at 18:17 PM EDT
Though results were positive, FDA determines that eteplirsen study was too small and asks for more data.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.